Equity awards expand holdings of Standard BioTools (LAB) senior executive

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received new equity awards as part of his compensation. He was granted options to buy 612,240 shares of common stock at an exercise price of $0.9846 per share, expiring on March 20, 2036. These options vest over four years, with 1/16 of the underlying shares vesting on May 20, 2026 and the rest in equal quarterly installments, contingent on continued service. He also received 272,107 restricted stock units that follow the same four‑year vesting schedule, each RSU converting into one share of common stock upon vesting. Following the stock grant, his directly held common stock position is 1,032,281 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Mackay Sean

Role SVP & Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	612,240	$0.00	--
Grant/Award	Common Stock	272,107	$0.00	--

Holdings After Transaction: Stock Option (Right to buy) — 612,240 shares (Direct); Common Stock — 1,032,281 shares (Direct)

Footnotes (1)

Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Stock options granted: 612,240 options Option exercise price: $0.9846 per share Option expiration: March 20, 2036 +3 more

6 metrics

Stock options granted 612,240 options Grant to Sean Mackay on March 20, 2026

Option exercise price $0.9846 per share Exercise price for 612,240 options

Option expiration March 20, 2036 Expiration date of granted options

RSUs granted 272,107 RSUs Restricted stock units granted March 20, 2026

RSU initial vest date May 20, 2026 1/16 of RSUs vest on this date

Common shares after grant 1,032,281 shares Direct common stock holdings after RSU award

Key Terms

restricted stock units, RSUs, Stock Option (Right to buy), exercise price, +1 more

5 terms

restricted stock units financial

"Represents restricted stock units ("RSUs") that vest over four years"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"1/16 of the RSUs vesting on May 20, 2026"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Stock Option (Right to buy) financial

"security_title: "Stock Option (Right to buy)""

exercise price financial

"conversion_or_exercise_price: "0.9846""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-03-20T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

04/08/2026 - 09:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mackay Sean

(Last)

(First)

(Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON

MASSACHUSETTS

02109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP & Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/20/2026		A		272,107⁽¹⁾	A	$0	1,032,281	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to buy)	$0.9846	03/20/2026		A		612,240		⁽²⁾	03/20/2036	Common Stock	612,240	$0	612,240	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

2. The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Sean Mackay by Samantha M. Silver, Attorney-in-Fact	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Sean Mackay receive from STANDARD BIOTOOLS (LAB)?

Sean Mackay received a grant of stock options and restricted stock units from STANDARD BIOTOOLS. The award includes 612,240 options to buy common shares and 272,107 restricted stock units, all structured as compensation rather than open-market purchases or sales.

How do Sean Mackay’s new restricted stock units at STANDARD BIOTOOLS (LAB) vest?

The 272,107 restricted stock units vest over four years. One-sixteenth vests on May 20, 2026, and the remaining units vest in equal quarterly installments afterward, provided Sean Mackay continues his service with STANDARD BIOTOOLS through each applicable vesting date.

What are the key terms of Sean Mackay’s new stock options at STANDARD BIOTOOLS (LAB)?

Sean Mackay’s stock options cover 612,240 shares of common stock at an exercise price of $0.9846 per share. They become exercisable 1/16 on May 20, 2026, with the balance vesting quarterly, and they expire on March 20, 2036, contingent on continued service.

How many STANDARD BIOTOOLS (LAB) common shares does Sean Mackay hold after these grants?

After the reported grants, Sean Mackay directly holds 1,032,281 shares of STANDARD BIOTOOLS common stock. This total reflects his position following the 272,107-share restricted stock unit award reported in the filing, which will convert into shares as the units vest over time.

Are Sean Mackay’s reported STANDARD BIOTOOLS (LAB) transactions open-market buys or compensation grants?

The reported transactions are compensation-related grants, not open-market buy or sell trades. Both the stock options and restricted stock units are coded as awards, with zero transaction price per share and vesting schedules tied to Sean Mackay’s continued service at the company.